

## Company Overview

HJLI specializes in developing and manufacturing bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has three product candidates: the porcine tissue based VenoValve®, which is intended to be surgically implanted in the deep venous system of the leg to treat Chronic Venous Insufficiency; the CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery, and a porcine tissue based heart valve, which based upon its relatively small size and increased output, is an ideal candidate for pediatric aortic/mitral valve replacement.

## Dr. Marc H. Glickman to Present at 6th Israeli Vascular Access Conference

Jan 15 2019, 8:00 AM EST

## Hancock Jaffe Announces End Points for First-in-Human VenoValve Study

Jan 9 2019, 8:00 AM EST

## Hancock Jaffe Receives Approval for First-in-Human VenoValve Study

Dec 17 2018, 8:00 AM EST

## Stock Overview

Symbol	HJLI
Exchange	Nasdaq
Market Cap	20.39m
Last Price	\$1.74
52-Week	\$1.33 - \$5.64

01/16/2019 04:00 PM EST

## Investor Relations

Robert A Berman
CEO
T: 949 261-2900

## Management Team

### Robert Berman

Chief Executive Officer and Director

### Robert Rankin

Chief Financial Officer

### Marc Glickman, M.D.

Senior Vice President and Chief Medical Officer

### Benedict Broennimann, M.D.

Chief Medical Officer, Outside of United States

### Chris Sarner

Vice President of Regulatory Affairs and Quality Assurance

---

## Hancock Jaffe Laboratories, Inc.

70 Doppler  
Irvine, CA 92618

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.